原發(fā)性肝癌是全球范圍內(nèi)高發(fā)病率且高致死率的惡性腫瘤之一。在原發(fā)性肝癌治療中，單一藥物往往受到不良反應(yīng)和耐藥性的限制，聯(lián)合用藥可以發(fā)揮多機(jī)制協(xié)同作用增加療效，降低毒副作用，延緩耐藥性。中藥單體具有良好的抗肝癌作用，較低的毒副作用以及可以拮抗化療藥物對(duì)正常組織細(xì)胞的損害等優(yōu)點(diǎn)常被用于與化療藥物聯(lián)合應(yīng)用治療肝癌。納米制劑可以使聯(lián)合使用的藥物在吸收分布上呈現(xiàn)出同步性，更好地發(fā)揮聯(lián)用藥物的協(xié)同作用，常被用于聯(lián)用藥物的負(fù)載和遞送。對(duì)化療藥物聯(lián)合中藥單體的優(yōu)勢(shì)、納米共載的優(yōu)勢(shì)以及用于肝癌治療的中藥單體與化療藥物共載納米制劑研究進(jìn)展進(jìn)行了綜述，為聯(lián)合用藥抗肝癌的研究提供參考。

Primary liver cancer is one of the malignant tumors with high incidence and mortality rates worldwide. In its treatment, single-drug therapies are often limited by toxic side effects and drug resistance. Combination therapy can exert multi-mechanism synergistic effects to enhance efficacy, reduce toxic side effects, and delay the development of drug resistance. Traditional Chinese medicine (TCM) monomers, which exhibit potent anti-liver cancer activity, lower toxicity, and the ability to counteract chemotherapy-induced damage to normal tissues, are frequently used in combination with chemotherapeutic drugs for liver cancer treatment. Nano-formulations enable synchronized absorption and distribution of combined drugs, thereby enhancing their synergistic effects, and are widely used for the loading and delivery of co-administered drugs. This article reviews the advantages of combining chemotherapeutic drugs with TCM monomers, the benefits of nano co-delivery, and recent research progress in co-delivery nano-formulations of TCM monomers and chemotherapeutic drugs for liver cancer treatment, aiming to provide insights for advancing research on combination therapy against liver cancer.

R286.2

廣西自然科學(xué)基金資助項(xiàng)目（2022GXNSFDA035063）；廣西自然科學(xué)基金資助項(xiàng)目（2023GXNSFAA026366）；國(guó)家自然科學(xué)基金資助項(xiàng)目（82360818）；國(guó)家自然科學(xué)基金資助項(xiàng)目（81960756）